NCT00185172View on ClinicalTrials.gov

Olmesartan in Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

2,333

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Essential Hypertension
Interventions
OTHER

placebo

Placebo oral tablets for 2 weeks

DRUG

olmesartan medoxomil

olmesartan medoxomil oral tablets for 8 weeks

DRUG

olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets

olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets

Trial Locations (8)

1130

Result Cro, Vienna

5352

IMRO TRAMARKO International bv, Berghem

8604

PFC Pharma Focus Consultants AG, Zurich

28002

Phidea S.L., Madrid

40122

Biokos Farma s.r.l., Bologna

52074

INPUT GmbG, Aachen

1070-274

EUROTRIALS Lda, Lisbon

Unknown

Inveresk Ltd., Edinburgh

All Listed Sponsors
lead

Sankyo Pharma Gmbh

INDUSTRY

NCT00185172 - Olmesartan in Essential Hypertension | Biotech Hunter | Biotech Hunter